BRAF and cancer: One study found that structurally distinct MEK inhibitor tool compounds (U0126, MIIC, PD98059) impair ETS Complex I activity in HL-60 cells.(62) Here we demonstrated that the first-in-class MEK inhibitor therapeutic Trm compromises oxidative metabolism in some, but not all, cancer cell types and that this effect is not dependent on the BRAF V600E oncogenic driver mutation.